Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Kadcyla

- PMLiVE

Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

Triple-negative breast cancer accounts for approximately 15% of all cases of the disease

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in first-line HER2-positive breast cancer

Up to 20% of patients with metastatic breast cancer are affected by HER2-positive disease

- PMLiVE

AstraZeneca’s Truqap recommended by NICE to treat advanced breast cancer

NICE estimates that around 1,100 patients will benefit from the twice-a-day tablet

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway approved by EC to treat breast cancer

Approximately 557,000 people are diagnosed with breast cancer every year in Europe

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu receives EC approval for HER2-low breast cancer

Approximately 557,000 people are diagnosed with breast cancer every year in Europe

- PMLiVE

Organon/Henlius announce EMA validation for Perjeta biosimilar HLX11

The reference medicine holds approvals for multiple HER2-positive breast cancer indications

- PMLiVE

Pfizer/Arvinas’ vepdegestrant shows promise in phase 3 breast cancer study

It is estimated that nearly 320,000 people will be diagnosed with the disease in the US this year

- PMLiVE

AstraZeneca’s camizestrant shows promise in phase 3 breast cancer study

More than two million cases of the disease were diagnosed globally in 2022

- PMLiVE

Novartis’ Kisqali granted MHRA approval to treat early breast cancer patients

The drug is already approved in the UK to treat advanced cases of the disease

- PMLiVE

UK government launches ‘landmark’ AI breast cancer screening trial

Approximately 55,000 cases of the disease are diagnosed every year in the UK

- PMLiVE

World Cancer Day – CoppaFeel! and NHS NELCA urge young people to ‘Check In’

The co-designed campaign aims to challenge misconceptions surrounding breast cancer

- PMLiVE

Roche shares positive overall survival results for Itovebi in advanced breast cancer

Approximately 56,800 new cases of breast cancer are diagnosed in the UK every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links